Back to News
Market Impact: 0.3
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
Source: GlobeNewswire
Healthcare & BiotechCompany Fundamentals
Cerenome secured a Florida Blue agreement covering its CNSide tumor cell and molecular tests. The agreement expands the company’s total contracted payer access to approximately 164 million covered lives.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
CNSY0.65
More News
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Why is the Chinese stock market missing the AI rally
- Why is T-Mobile stock tumbling today?
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit
- Wall Street Week | Michigan Manufacturing, AI Debt Investments, Baby Bonds, Canadian Coal Fight